Moretti J L, Duran Cordobes M, Starzec A, de Beco V, Vergote J, Benazzouz F, Boissier B, Cohen H, Safi N, Piperno-Neumann S, Kouyoumdjian J C
Laboratory of Radiopharmacology, Upres 2360 IOCMH, Bobigny, France.
J Nucl Med. 1998 Jul;39(7):1214-8.
It was reported recently that 99mTc-hexakis-2-methoxyisobutyl isonitrile (MIBI) uptake is drastically reduced in cancer cells that express the multidrug resistance (MDR) product, Pgp 170 kDa (Pgp), suggesting that 99mTc-MIBI is a transport substrate for this transmembrane glycoprotein. In our study, we explored if another pump, a multidrug resistance-associated protein (MRP), could affect 99mTc-MIBI uptake. In addition, we studied the involvement of intracellular glutathione (GSH) as a modulator of 99mTc-MIBI uptake by both Pgp and MRP proteins.
MDR1 and MRP gene expression in seven human tumor cell lines was determined on a transcriptional level by reverse transcriptase polymerase chain reaction and on a protein level using immunocytochemistry. Technetium-99m-MIBI uptake was quantified by measuring radioactivity retained in the cells incubated at 37 degrees C in the presence or absence of buthionine sulfoximine (BSO), which depletes cellular GSH. The cellular GSH content was determined with Ellman's reagent.
Cell lines were classified according to their phenotypic characteristics: 1/MRP-/Pgp-: breast cancer cells (MCF7), lung carcinoma cells (H69S) and mouth epidermoid tumor cells (KB 3.1), 2/MRP-/Pgp+: MCF7 mdr+, KBA.1; and 3/MRP+/Pgp-: small-cell lung carcinoma (H69 AR and A 549). Technetium-99m-MIBI uptake was significantly lower in cells expressing MRP as well as Pgp compared to MRP/Pgp cells. Depletion of GSH by BSO resulted in an increase of 99mTc-MIBI uptake in multidrug resistant cells overexpressing MRP but not expressing Pgp.
Technetium-99m-MIBI is extruded by both Pgp and MRP efflux pumps. However, MRP action is indirect and involves intracellular GSH for a presumed interaction with the 99mTc-MIBI before its effLux. Technetium-99m-MIBI seems to be a good candidate for a noninvasive marker to diagnose MDR1 related to Pgp and MRP expression in tumors of different origin.
最近有报道称,在表达多药耐药(MDR)产物Pgp 170 kDa(Pgp)的癌细胞中,99mTc-六甲基-2-甲氧基异丁基异腈(MIBI)摄取显著降低,这表明99mTc-MIBI是这种跨膜糖蛋白的转运底物。在我们的研究中,我们探讨了另一种转运蛋白——多药耐药相关蛋白(MRP)是否会影响99mTc-MIBI的摄取。此外,我们研究了细胞内谷胱甘肽(GSH)作为Pgp和MRP蛋白介导的99mTc-MIBI摄取调节剂的作用。
通过逆转录聚合酶链反应在转录水平以及使用免疫细胞化学在蛋白水平测定七种人类肿瘤细胞系中的MDR1和MRP基因表达。通过测量在37℃下存在或不存在丁硫氨酸亚砜胺(BSO,可耗尽细胞内GSH)孵育的细胞中保留的放射性来定量99mTc-MIBI摄取。用埃尔曼试剂测定细胞内GSH含量。
根据细胞系的表型特征进行分类:1/MRP-/Pgp-:乳腺癌细胞(MCF7)、肺癌细胞(H69S)和口腔表皮样瘤细胞(KB 3.1);2/MRP-/Pgp+:MCF7 mdr+、KBA.1;3/MRP+/Pgp-:小细胞肺癌(H69 AR和A 549)。与MRP/Pgp双阴性细胞相比,表达MRP以及Pgp的细胞中99mTc-MIBI摄取显著降低。BSO耗尽GSH导致过表达MRP但不表达Pgp的多药耐药细胞中99mTc-MIBI摄取增加。
99mTc-MIBI可被Pgp和MRP外排泵排出。然而,MRP的作用是间接的,在其外排之前,可能涉及细胞内GSH与99mTc-MIBI的相互作用。99mTc-MIBI似乎是一种用于诊断与不同来源肿瘤中Pgp和MRP表达相关的MDR1的非侵入性标志物的良好候选物。